Evidence map›Paper›PMID 39710565›Full record

ArticleClinical lymphoma, myeloma & leukemia2025

Artificial Intelligence Assessment of Chest Radiographs for COVID-19.

Koji Sasaki, Guillermo Garcia-Manero, Masayuki Nigo, Elias Jabbour, Farhad Ravandi, William G Wierda, Nitin Jain, Koichi Takahashi, Guillermo Montalban-Bravo, Naval G Daver and 10 more

Abstract read
In one paragraph

Article in Clinical lymphoma, myeloma & leukemia, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Koji SasakiDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX; Department of Hematology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan. Electronic address: ksasaki1@mdanderson.org.
Guillermo Garcia-ManeroDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX.
Masayuki NigoDivision of Infectious Diseases, Department of Internal Medicine, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, TX.
Elias JabbourDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX.
Farhad RavandiDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX.
William G WierdaDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX.
Nitin JainDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX.
Koichi TakahashiDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX.
Guillermo Montalban-BravoDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX.
Naval G DaverDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX.
Philip A ThompsonDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX.
Naveen PemmarajuDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX.
Dimitrios P KontoyiannisDepartment of Infectious Disease, The University of Texas MD Anderson Cancer Center, Houston, TX.
Junya SatoDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX.
Sam KarimaghaeiMcGovern Medical School, The University of Texas Health Science Center at Houston, Houston, TX.
Kelly A SoltysiakDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX.
Issam I RaadDepartment of Infectious Disease, The University of Texas MD Anderson Cancer Center, Houston, TX.
Hagop M KantarjianDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX.
Brett W CarterDepartment of Diagnostic Radiology, The University of Texas MD Anderson Cancer Center, Houston, TX.
D3CODE Research Team

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Scott Kopetz · 1985 to 2026
$290.8M
Deep Learning Based Pharmacokinetic Model for VancomycinR01AI175699 · NIAID · METHODIST HOSPITAL RESEARCH INSTITUTE · PI NIGO, MASAYUKI · 2023 to 2025
$2.4M
NCI NIH HHS P30 CA016672NIAID NIH HHS R01 AI175699
6 · The paper itself

Abstract

backgroundThe sensitivity of reverse-transcription polymerase chain reaction (RT-PCR) is limited for diagnosis of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Chest computed tomography (CT) is reported to have high sensitivity; however, given the limited availability of chest CT during a pandemic, the assessment of more readily available imaging, such as chest radiographs, augmented by artificial intelligence may substitute for the detection of the features of coronavirus disease 2019 (COVID-19) pneumonia.

methodsWe trained a deep convolutional neural network to detect SARS-CoV-2 pneumonia using publicly available chest radiography imaging data including 8,851 normal, 6,045 pneumonia, and 200 COVID-19 pneumonia radiographs. The entire cohort was divided into training (n = 13,586) and test groups (n = 1510). We assessed the accuracy of prediction with independent external data.

resultsThe sensitivity and positive predictive values of the assessment by artificial intelligence were 96.8% and 90.9%, respectively. In the first external validation of 204 chest radiographs among 107 patients with confirmed COVID-19, the artificial intelligence algorithm correctly identified 174 (85%) chest radiographs as COVID-19 pneumonia among 97 (91%) patients. In the second external validation with 50 immunocompromised patients with leukemia, the higher probability of the artificial intelligence assessment for COVID-19 was correlated with suggestive features of COVID-19, while the normal chest radiographs were closely correlated with the likelihood of normal chest radiographs by the artificial intelligence prediction.

conclusionsThe assessment method by artificial intelligence identified suspicious lung lesions on chest radiographs. This novel approach can identify patients for confirmatory chest CT before the progression of COVID-19 pneumonia.

Indexed as

Artificial IntelligenceCOVID-19Radiography, ThoracicAgedDeep LearningFemaleHumansLungMaleMiddle AgedNeural Networks, ComputerSARS-CoV-2Sensitivity and SpecificityTomography, X-Ray Computedartificial intelligencechest radiographCOVID-19

Identifiers

PMID39710565
PMCPMC11993350

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.